RESUMO
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic and symmetric in-flammation. Our previous research revealed an imbalance in the gut flora of RA patients and showed that certain gut microbiota can accelerate RA progression by enhancing vitamin C degradation. However, it is unclear whether vitamin C supplementation could improve the gut microbiota to prevent the development of arthritis by interfering with the gut-joint axis. In this work, we aimed to evaluate the effects of vitamin C in regulating the gut microbiota and to elucidate its potential role in the onset and progression of RA in a mouse model, thus providing a basis for the development of new intervention strategies and treatments for RA. In this study, collagen-induced arthritis (CIA) mouse models, biochemical, histological and 16S rRNA microbiological methods were used to investigate the role and possible mechanism of vitamin C in rheumatoid arthritis. The results showed that treatment of CIA mice with vitamin C effectively rescued the gut mi-crobiota imbalance and suppressed the inflammatory response associated with RA, and effectively alleviated arthritis symptoms in mice in which levels of the pro-inflammatory cytokines IL-6 and TNF-α were specifi-cally reduced. In conclusion, our results demonstrate the potential of vitamin C as a potential therapeutic choice for RA.
Assuntos
Artrite Experimental , Artrite Reumatoide , Ácido Ascórbico , Microbioma Gastrointestinal , Animais , Ácido Ascórbico/uso terapêutico , Ácido Ascórbico/administração & dosagem , Ácido Ascórbico/farmacologia , Microbioma Gastrointestinal/efeitos dos fármacos , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/microbiologia , Camundongos , Artrite Experimental/tratamento farmacológico , Artrite Experimental/microbiologia , Artrite Experimental/imunologia , Masculino , Camundongos Endogâmicos DBA , Fator de Necrose Tumoral alfa/metabolismo , Interleucina-6/metabolismo , Modelos Animais de Doenças , RNA Ribossômico 16S/genéticaRESUMO
Icariin (ICA) is the main active flavonoid glucoside from herbs of the genus Epimedium; in traditional Chinese medicine, these herbs have long been prescribed for the treatment of bone fractures and osteoporosis. Several studies have shown that treatment with ICA can increase osteogenic differentiation and reduce bone loss in vivo and in vitro. However, the definite signaling pathway of this osteogenic effect remains unclear. In this study, we selected bone morphogenetic protein 2 (BMP2)-induced osteoblastic differentiation of multipotent mesenchymal progenitor C2C12 cells as a model of osteoblast differentiation. We investigated the effects of ICA on C2C12 cells osteogenic differentiation and the underlying molecular mechanisms. We found that ICA could enhance BMP2-mediated osteoblastic differentiation of C2C12 cells in a dose-dependent manner. Treatment with ICA activated the cAMP/PKA/CREB signaling axis in a time-dependent manner. Blocking cAMP signaling using the PKA selective inhibitor H89 significantly inhibited the stimulatory effect of ICA on osteogenesis. Therefore, the osteoinductive potential and the low cost of ICA indicate that it is a promising alternative treatment or promoter for enhancing the therapeutic effects of BMP2.
Assuntos
Proteína Morfogenética Óssea 2/farmacologia , Reabsorção Óssea/tratamento farmacológico , Diferenciação Celular/efeitos dos fármacos , Flavonoides/farmacologia , Osteogênese/efeitos dos fármacos , Animais , Reabsorção Óssea/genética , Reabsorção Óssea/patologia , AMP Cíclico/genética , Epimedium/química , Fraturas Ósseas/tratamento farmacológico , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/farmacologia , Medicina Tradicional Chinesa , Células-Tronco Mesenquimais/efeitos dos fármacos , Camundongos , Osteoblastos/efeitos dos fármacos , Osteogênese/genética , Osteoporose/tratamento farmacológico , Transdução de Sinais/efeitos dos fármacosRESUMO
OBJECTIVE: Tumour necrosis factor alpha (TNF-α) signalling plays a central role in the pathogenesis of various autoimmune diseases, particularly inflammatory arthritis. This study aimed to repurpose clinically approved drugs as potential inhibitors of TNF-α signalling in treatment of inflammatory arthritis. METHODS: In vitro and in vivo screening of an Food and Drug Administration (FDA)-approved drug library; in vitro and in vivo assays for examining the blockade of TNF actions by fexofenadine: assays for defining the anti-inflammatory activity of fexofenadine using TNF-α transgenic (TNF-tg) mice and collagen-induced arthritis in DBA/1 mice. Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine's anti-TNF activity on cPLA2. RESULTS: Serial screenings of a library composed of FDA-approved drugs led to the identification of fexofenadine as an inhibitor of TNF-α signalling. Fexofenadine potently inhibited TNF/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) signalling in vitro and in vivo, and ameliorated disease symptoms in inflammatory arthritis models. cPLA2 was isolated as a novel target of fexofenadine. Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505. Further, deletion of cPLA2 abolished fexofenadine's anti-TNF activity. CONCLUSION: Collectively, these findings not only provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-α and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases.
Assuntos
Artrite Experimental/tratamento farmacológico , Fosfolipases A2 Citosólicas/efeitos dos fármacos , Terfenadina/análogos & derivados , Inibidores do Fator de Necrose Tumoral/farmacologia , Animais , Camundongos , Camundongos Endogâmicos DBA , Camundongos Transgênicos , Transdução de Sinais/efeitos dos fármacos , Terfenadina/farmacologia , Fator de Necrose Tumoral alfa/antagonistas & inibidoresRESUMO
Wilson's disease (WD) is an autosomal recessive disease caused by a mutation of the ATP7B gene, resulting in abnormal copper metabolism. The major clinical features of WD include liver disease, neurological disorders, K-F rings, and osteoporosis. The prevalence of WD in China is higher than that in Western countries. Early diagnosis and lifelong treatment will lead to better outcomes. Drugs such as sodium dimercaptosuccinate (Na-DMPS), Zn, and Gandou Decoction can be used to treat WD. Some studies have shown that the combination of traditional Chinese medicine and Western medicine is the best approach to treating WD. In order to identify better treatments, this article describes the specific clinical symptoms of Wilson's disease, its diagnosis, and treatment options.
RESUMO
Fibroblast growth factor-2 (FGF2) inhibits osteoblast mineralization, but the mechanism by which it does so is not fully understood. Matrix vesicles (MVs) play an essential role in the initiation of mineralization, so the current study examined the effect of FGF2 on the functioning of MVs to investigate this mechanism. This study found that FGF2 significantly inhibited differentiation and mineralization of osteoblast-like Saos-2 cells, as indicated by down-regulation of mRNA expression of the osteogenic master regulator runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and collagen 1 alpha 1 (Colla1), and by decreasing the formation of bone nodules. MVs were isolated from Saos-2 cells cultured in osteogenic medium supplemented with and without FGF2 and their presence was verified using electron microscopy and Western blotting. FGF2 markedly reduced the ALP activity of and in vitro mineralization by MVs. These findings suggest that FGF2 inhibits osteoblast mineralization by limiting the capacity of MVs.